Presentations & Publications

Presentations & Publications

Eptinezumab Presentations and Publications

PROMISE 1 Presentations:

  • Saper J et al, Primary Results of PROMISE-1 (Prevention Of Migraine via Intravenous eptinezumab Safety and Efficacy-1) Trial: a Phase 3, Randomized, Double-blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Eptinezumab for Prevention of Frequent Episodic Migraines. Scientific Platform Presentation by Silberstein S at the American Academy of Neurology (AAN) 2018 Annual Meeting.
  • Lipton R et al, Increased Migraine-Free Intervals With Eptinuzumab Were Associated With Improved Health-Related Quality-of-Life Outcomes Through Week 12: Results From the Phase 3 PROMISE-1 Trial. Scientific Platform Presentation Presented at the American Academy of Neurology (AAN) 2018 Annual Meeting.

 

PROMISE 1 Posters:

  • Smith T et al, Eptinezumab Achieved Meaningful Reductions in Migraine Activity Within 24 Hours That Were Sustained Through Week 12: Results From PROMISE-1 (PRevention Of Migraine via Intravenous eptinezumab Safety and Efficacy-1) Phase 3 Trial. Poster Presented at the American Academy of Neurology (AAN) 2018 Annual Meeting.
  • Spierings ELH et al, Repeat Infusions of Eptinezumab Associated With Greater Migraine Reductions and Longer Migraine-Free Intervals: Results From the Phase 3 PROMISE-1 Trial. Poster Presented at the American Academy of Neurology (AAN) 2018 Annual Meeting.
  • Silberstein S et al, Eptinezumab Reduced Migraine Frequency, Duration, and Pain Intensity Through Week 24: Results From the Phase 3 PROMISE-1 Trial. Poster Presented at the American Academy of Neurology (AAN) 2018 Annual Meeting.

 

PROMISE 2 Presentations:

  • Lipton R et al, A Phase 3, Randomized, Double-blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Eptinezumab for the Preventive Treatment of Chronic Migraine: Results of the PROMISE-2 (PRevention Of Migraine via Intravenous eptinezumab Safety and Efficacy-2) Trial. Clinical Trials Plenary Presentation at the American Academy of Neurology (AAN) 2018 Annual Meeting

 

PROMISE 2 Posters:

  • Kudrow D et al, Eptinezumab Achieved Meaningful Reductions in Migraine Activity As Early As Day 1 and Were Sustained Through Week 12: Results From PROMISE-2 (PRevention Of Migraine via Intravenous eptinezumab Safety and Efficacy-2) Phase 3 Trial in Chronic Migraine. Emerging Science Poster Presented at the American Academy of Neurology (AAN) 2018 Annual Meeting.
  • Eptinezumab Reduced Migraine Frequency and Triptan/Ergotamine Use Over Weeks 1-12, and Improved HIT-6 Scores at Months One and Three: Results From the Phase 3 PROMISE-2 Trial in Chronic Migraine. Emerging Science Poster Presented at the American Academy of Neurology (AAN) 2018 Annual Meeting.